Buprenorphine use in California
(The state policy, the number of licensed doctors etc)
Buprenorphine, a FDA approved drug is a derivative of thebaine. This drug is an opioid and dependence leads to serious illness. Buprenorphine has been marketed as parenteral analgesic Buprenex in the United States. This drug reacts much slowly as compared to morphine and can be administrated sublingually as an analgesic. FDA approved Subutex, as a buprenorphine/naloxone combination product and Suboxone as medication for treatment of opioid addiction. Subutex and Suboxone are the first narcotic drugs openly available under the US Drug Act (DATA) of 2003. US physicians prescribe Subutex and Suboxone for the treatment of opiate dependence.
Records show that buprenorphine has abuse potential and may cause dependency. Numerous deaths have been recorded due to overdose of intravenously injected buprenorphine. Buprenorphine is metabolized primarily by n-dealkylation to form glucuronide-buprenorphine and glucuronide-norbuprenorphine. Buprenorphine is safer to use as compared to other opioid agonists because of its bioavailability and ceiling effect. Buprenorphine side effects are mainly seen when the dosage exceeds 16–32 mg range in tablets. Higher dose of Buprenorphine produces more side effects. Buprenorphine sometimes causes respiratory depression. Chronic use of Buprenorphine does not cause any organ damage, though it increases the liver enzymes. None of the research reports suggest any evidence-stating disturbance of psychomotor performance or cognitive buprenorphine continuance dosage.
Buprenorphine is abusable because of its opioid agonist effect and some individuals get addicted to it. By combining Buprenorphine and Naloxone, you can actually reduce likelihood of diversion and abuse. Moderate bioavailability is found in sublingual buprenorphine, whereas sublingual naloxone has poor bioavailability. Therefore, when the buprenorphine and naloxone tablet are mixed and consumed sublingually then buprenorphine loses its opioid agonist effect and thus does not cause opioid withdrawal symptoms. Under normal circumstances buprenorphine precipitates withdrawal symptoms in addicted individuals. Buprenorphine addiction treatment is given to those individuals who are neutrally diagnosed as opioid addicts or those who wish to follow the treatment precautions rigidly due to the agreement signed before following the treatment. The patients, before signing up for this treatment, should check for allergic reaction to the buprenorphine therapy. Patients should always agree and go ahead with buprenorphine de addiction treatment after understanding all the treatment options. There are three types of buprenorphine treatment phase: induction, stabilization, and maintenance.
State policy-
The nations war against drugs intensified during the 1980’s and 90’s and California also followed this trend by increasing the punishment and prison statements for drug peddlers. Hundreds of drug peddlers were arrested, imprisoned, and convicted thus disrupting their family lives and reducing their future job prospects. California’s drug policy faced a complete turnaround in the form of Proposition 36 -The Substance Abuse and Crime Prevention Act. This Act came into affect on November 7, 2000 and proposed treating drugs abuse as a primary health issue, rather than a criminal offense.
(The state policy, the number of licensed doctors etc)
Buprenorphine, a FDA approved drug is a derivative of thebaine. This drug is an opioid and dependence leads to serious illness. Buprenorphine has been marketed as parenteral analgesic Buprenex in the United States. This drug reacts much slowly as compared to morphine and can be administrated sublingually as an analgesic. FDA approved Subutex, as a buprenorphine/naloxone combination product and Suboxone as medication for treatment of opioid addiction. Subutex and Suboxone are the first narcotic drugs openly available under the US Drug Act (DATA) of 2003. US physicians prescribe Subutex and Suboxone for the treatment of opiate dependence.
Records show that buprenorphine has abuse potential and may cause dependency. Numerous deaths have been recorded due to overdose of intravenously injected buprenorphine. Buprenorphine is metabolized primarily by n-dealkylation to form glucuronide-buprenorphine and glucuronide-norbuprenorphine. Buprenorphine is safer to use as compared to other opioid agonists because of its bioavailability and ceiling effect. Buprenorphine side effects are mainly seen when the dosage exceeds 16–32 mg range in tablets. Higher dose of Buprenorphine produces more side effects. Buprenorphine sometimes causes respiratory depression. Chronic use of Buprenorphine does not cause any organ damage, though it increases the liver enzymes. None of the research reports suggest any evidence-stating disturbance of psychomotor performance or cognitive buprenorphine continuance dosage.
Buprenorphine is abusable because of its opioid agonist effect and some individuals get addicted to it. By combining Buprenorphine and Naloxone, you can actually reduce likelihood of diversion and abuse. Moderate bioavailability is found in sublingual buprenorphine, whereas sublingual naloxone has poor bioavailability. Therefore, when the buprenorphine and naloxone tablet are mixed and consumed sublingually then buprenorphine loses its opioid agonist effect and thus does not cause opioid withdrawal symptoms. Under normal circumstances buprenorphine precipitates withdrawal symptoms in addicted individuals. Buprenorphine addiction treatment is given to those individuals who are neutrally diagnosed as opioid addicts or those who wish to follow the treatment precautions rigidly due to the agreement signed before following the treatment. The patients, before signing up for this treatment, should check for allergic reaction to the buprenorphine therapy. Patients should always agree and go ahead with buprenorphine de addiction treatment after understanding all the treatment options. There are three types of buprenorphine treatment phase: induction, stabilization, and maintenance.
State policy-
The nations war against drugs intensified during the 1980’s and 90’s and California also followed this trend by increasing the punishment and prison statements for drug peddlers. Hundreds of drug peddlers were arrested, imprisoned, and convicted thus disrupting their family lives and reducing their future job prospects. California’s drug policy faced a complete turnaround in the form of Proposition 36 -The Substance Abuse and Crime Prevention Act. This Act came into affect on November 7, 2000 and proposed treating drugs abuse as a primary health issue, rather than a criminal offense.
For additional information on addiction treatment or the drug
Suboxone,
Call now 1-888-Suboxone or 1-888-782-6966
E-mail: Support@SoftLandingRecovery.com>
Content provided by the Editorial Board.
This article is written by a freelance writer. It might not reflect the views and opinions of Soft Landing ltd. or its staff but has been placed here
so that our visitors may get an idea of how others think of the topic.
Information on this page last updated on 06/10/2007